GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » EV-to-Revenue

Evotec SE (XTER:EVT) EV-to-Revenue : 1.15 (As of Jun. 25, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Evotec SE EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Evotec SE's enterprise value is €905.6 Mil. Evotec SE's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was €788.2 Mil. Therefore, Evotec SE's EV-to-Revenue for today is 1.15.

The historical rank and industry rank for Evotec SE's EV-to-Revenue or its related term are showing as below:

XTER:EVT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8   Med: 6.5   Max: 14.61
Current: 1.15

During the past 13 years, the highest EV-to-Revenue of Evotec SE was 14.61. The lowest was 0.80. And the median was 6.50.

XTER:EVT's EV-to-Revenue is ranked better than
75.72% of 972 companies
in the Drug Manufacturers industry
Industry Median: 2.405 vs XTER:EVT: 1.15

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-25), Evotec SE's stock price is €6.882. Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €4.44. Therefore, Evotec SE's PS Ratio for today is 1.55.


Evotec SE EV-to-Revenue Historical Data

The historical data trend for Evotec SE's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE EV-to-Revenue Chart

Evotec SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.89 11.59 3.33 4.85 1.88

Evotec SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 2.23 1.59 1.88 0.96

Competitive Comparison of Evotec SE's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Evotec SE's EV-to-Revenue falls into.


;
;

Evotec SE EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Evotec SE's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=905.582/788.219
=1.15

Evotec SE's current Enterprise Value is €905.6 Mil.
Evotec SE's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €788.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evotec SE  (XTER:EVT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Evotec SE's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.882/4.442
=1.55

Evotec SE's share price for today is €6.882.
Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.44.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evotec SE EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Evotec SE's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Executives
Dr. Christian Wojczewski Board of Directors
Aurélie Dalbiez Board of Directors
Prof. Dr. Iris Löw-friedrich Supervisory Board
Dr. Craig Johnstone Board of Directors
Dr. Cord Dohrmann Board of Directors
Dr. Werner Lanthaler Board of Directors